A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma
This study looks at a personalized cancer vaccine called autogene cevumeran combined with an immunotherapy drug called nivolumab, compared to nivolumab alone. The goal is to see how well these treatments work to prevent cancer from returning after surgery for muscle-invasive urinary tract cancer.
You may be able to join if you have had surgery to remove muscle-invasive bladder or urinary tract cancer that has not spread to distant parts of the body. There are specific rules about previous treatments and surgeries that the study team will review with you.
Participants receive either a combination of the personalized vaccine and the immunotherapy drug, or just the immunotherapy drug alone. The main focus now is ensuring the ongoing safety and treatment continuity for patients currently enrolled in the study.
The study has locations in New Jersey, United States. It is currently active for existing participants, but it is not recruiting new patients at this time.
- 1Testing a personalized cancer vaccine combined with immunotherapy
- 2Focuses on patients who had surgery for muscle-invasive urinary tract cancer
- 3Currently active only for participants already enrolled in the study
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.